Trial Profile
A Phase 1b Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 12 Aug 2020 Planned End Date changed from 1 Jul 2024 to 1 Jan 2025.
- 12 Aug 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jan 2021.
- 12 Aug 2020 Status changed from recruiting to active, no longer recruiting.